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Abstract: Obesity and dyslipidemia are major risk factors for the development of cardiovascular
diseases (CVD). Quercetin, a natural flavonoid, lowers plasma triglycerides (TG) in human
intervention studies, and its intake is associated with lower CVD risk. The aim of this study
was to elucidate the mechanism by which quercetin lowers plasma TG levels in diet-induced
obesity. C57Bl/6J mice received a high-fat diet (45% of calories derived from fat) with or
without quercetin (0.1% w/w) for 12 weeks. Quercetin decreased plasma TG levels from
nine weeks onwards (−19%, p < 0.05), without affecting food intake, body composition,
or energy expenditure. Mechanistically, quercetin did not reduce intestinal fatty acid (FA)
absorption. Rather, quercetin induced a slight reduction in liver Apob expression (−13%,
p < 0.05), which suggests decreased very-low density lipoprotein-TG production. Interestingly,
quercetin also markedly increased the uptake of [3H]oleate, which was derived from glycerol
tri[3H]oleate-labeled lipoprotein-like particles by subcutaneous white adipose tissue (sWAT, +60%,
p < 0.05). Furthermore, quercetin also markedly increased mRNA expression of Ucp1 (+229%, p < 0.05)
and Elovl3 (+138%, p < 0.05), specifically in sWAT. Accordingly, only quercetin-treated animals
showed uncoupling protein-1 protein-positive cells in sWAT, which is fully compatible with increased
browning. Taken together, the TG-lowering effect of quercetin may, at least in part, be due to increased
TG-derived FA uptake by sWAT as a consequence of browning.
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1. Introduction
Cardiovascular diseases (CVD) are the number one cause of death worldwide. Obesity and
dyslipidemia are major risk factors for developing CVD [1–3]. Super foods and other natural products,
including flavonoids, have become increasingly popular as potential strategies to target these risk
factors. Quercetin is a naturally occurring flavonoid that is present in fruits and vegetables [4].
Interestingly, epidemiological studies show that increased quercetin intake is associated with a reduced
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risk for developing CVD [5]. In a preclinical study, quercetin supplementation indeed reduced
atherosclerosis development [6]. Furthermore, quercetin supplementation attenuates body weight
gain [7–9] and lipid deposition in the liver [10,11], as well as white adipose tissue depots [12] of animals
on a high-fat diet. In addition, quercetin lowers plasma triglyceride (TG) levels in mice [7,9,13] and
humans [14], thereby targeting another risk factor for CVD.
The exact mechanism underlying the TG-lowering effect of quercetin and the organs involved
have not yet been elucidated. Interestingly, a recent in vitro study showed that quercetin induces
the browning of 3T3-L1 white adipocytes [15], as they adapted a more brown-like phenotype,
including higher mRNA expression of the uncoupling protein 1 (UCP-1) [16]. Of note, we recently
showed that browned white adipose tissue (WAT) depots increase their uptake of TG-derived
fatty acids (FA) from the circulation compared with the same WAT depots in mice that lack the
browning stimulus [17,18]. In addition, brown adipose tissue (BAT) is a major contributor to TG
metabolism [19,20]. When activated by e.g., cold, BAT enhances the oxidation of intracellular
FA in both mice [17] and humans [21], which causes the rapid depletion of intracellular TG
stores. As a consequence, BAT takes up large amounts of TG-derived FA in a lipoprotein lipase
(LPL)-dependent manner and combusts these to generate heat in a process that is dependent on
mitochondrial UCP-1 [20,22].
Whether BAT and (browned) WAT are involved in the beneficial effects of quercetin with respect
to the reduction of plasma TG remains to be determined. Therefore, in the current study, we aimed at
elucidating the mechanism by which quercetin lowers plasma TG levels by studying whole body lipid
metabolism with the focus on BAT and WAT in diet-induced obese mice.
2. Results
2.1. Quercetin Reduces Plasma Triglyceride Levels without Affecting Body Composition, Food Intake,
and Energy Expenditure
In order to assess the effect of quercetin on body composition, plasma lipids, and energy balance,
C57Bl/6J mice were fed a high-fat diet (HFD) with or without 0.1% (w/w) quercetin for 12 weeks.
Quercetin neither affected body weight (mean body weight after 12 weeks 45.2 ± 2.5 g in control
and 47.4 ± 3.3 g in quercetin-treated animals; Figure 1A) nor body composition with respect to lean
and fat mass (Figure 1B). In line with these data, the organ weight of spleen, gonadal WAT (gWAT),
and interscapular BAT (iBAT) at necropsy were unaffected by quercetin. We only found liver weight
to be increased (+13%, p < 0.05; Figure S1A). Of note, quercetin lowered plasma TG levels from
nine weeks onwards (up to −19%, p < 0.05; Figure 1C). Furthermore, quercetin treatment increased
plasma total cholesterol levels—mainly due to increased cholesterol in the high density lipoprotein
fraction (Figure S1B,C)—decreased plasma free FA (FFA) levels, and did not affect plasma glucose
(Figure S1D,E). The lowering in plasma TG levels by quercetin could not be explained by a lower
daily food intake, since daily food intake was not persistently affected by quercetin (Figure 1D).
To determine whether quercetin influenced whole body energy expenditure and substrate utilization,
mice were placed in metabolic cages in the third week of treatment. Quercetin did not affect total
energy expenditure (EE), fat, or glucose oxidation (Figure 1E–G). The respiratory exchange ratio (RER)
and physical activity were also unaltered (Figure S1F,G). Taken together, quercetin reduced plasma TG
without affecting body weight, body composition, food intake, and energy expenditure.
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Figure 1. Quercetin reduces plasma triglyceride levels without affecting body composition, food 
intake and energy expenditure. C57Bl/6J mice were fed a high-fat diet (HFD) +/− quercetin (0.1% 
w/w) for 12 weeks. Body weight was measured weekly (A). Body composition was determined (B). 
Plasma triglycerides were determined before and every three weeks during the intervention (C). 
Food intake was determined weekly (D). In the third week of treatment, animals were placed in fully 
automatic metabolic cages for an assessment of total energy expenditure (E), fat oxidation (F), and 
glucose oxidation (G). Data are represented as mean ± SEM (n = 8–10), * p < 0.05 versus control. 
2.2. Quercetin Reduces Hepatic ApoB Expression and Increases Uptake of TG-Derived FA by sWAT 
Plasma TG levels are determined by the balance between intestinal TG uptake, hepatic very-low 
density lipoprotein (VLDL)-TG production, and VLDL-TG clearance by LPL-expressing peripheral 
organs. We first assessed total fecal output, measured over 24 h, which was unaltered after two and 
10 weeks of quercetin treatment (Figure 2A). Interestingly, FFA content in feces was reduced after 10 
weeks of quercetin treatment (−39%, p < 0.05; Figure 2B), suggesting enhanced rather than decreased 
intestinal TG absorption. We next focused on the effect of quercetin on liver lipid metabolism. 
Although quercetin increased liver weight (Figure S1A), quercetin did not affect liver lipid content 
(Figure S2A,B). The activation of xenobiotic sensing nuclear receptor pregnane X receptor (PXR), as 
the underlying cause for the increased liver weight, was excluded, since Pxr expression and the 
expression of the PXR target gene Cyp3a11 remained unchanged (Figure S2C). The hepatic 
expression of lipid synthesis and oxidation marker acyl-CoA synthetase long-chain family member 1 
(Acsl1) was unaffected, and lipid synthesis marker acetyl-CoA carboxylase 2 (Acc2) tended to be 
increased after quercetin treatment (Figure 2C). 
To assess the effect of quercetin on VLDL-TG production, we determined the mRNA expression 
of hepatic microsomal triglyceride transfer protein (Mttp) and apolipoprotein B (Apob), which are 
both involved in hepatic VLDL assembly and secretion (Figure 2C). Of note, quercetin decreased 
Apob expression (−13%, p < 0.05; Figure 2C), which may indicate lower VLDL production. 
To investigate whether quercetin reduced plasma TG levels due to an increased clearance of 
TG-rich lipoproteins, we determined the kinetics of intravenous injected [3H]triolein (TO) labeled 
TG-rich lipoprotein-like particles, and studied the plasma clearance of [3H]TO and organ uptake of 
[3H]TO-derived [3H]oleate in mice treated with quercetin for 12 weeks. The plasma clearance of 
[3H]TO was slightly accelerated in the quercetin-treated group (Figure 2D). An uptake of 3H per 
gram organ was decreased in the liver (−22%, p < 0.05), but this effect disappeared when data were 
Figure 1. Quercetin reduces plasma triglyceride levels without affecting body composition, food intake
and energy expenditure. C57Bl/6J mice were fed a high-fat diet (HFD) +/− quercetin (0.1% w/w)
for 12 weeks. Body weight was measured weekly (A). Body composition was determined (B).
Plasma triglycerides were determined before and every three weeks during the intervention (C).
Food intake was determined weekly (D). In the third week of treatment, animals were placed in
fully automatic metabolic cages for an assessment of total energy expenditure (E), fat oxidation (F),
and glucose oxidation (G). Data are represented as mean ± SEM (n = 8–10), * p < 0.05 versus control.
2.2. Quercetin Reduces Hepatic ApoB Expression and Increases Uptake of TG-Derived FA by sWAT
Plasma TG levels are determined by the balance between intestinal TG uptake, hepatic very-low
density lipoprotein (VLDL)-TG production, and VLDL-TG clearance by LPL-expressing peripheral
organs. We first assessed total fecal output, measured over 24 h, which was unaltered after two
and 10 weeks of quercetin treatment (Figure 2A). Interestingly, FFA content in feces was reduced
after 10 weeks of quercetin treatment (−39%, p < 0.05; Fig re 2B), suggesting enhance rather than
decreased intestinal G bsorption. We next focused o th effe t of querceti on liver lipid metabolism.
Although quercetin increased liver weight (Figure S1A), quercetin did not affect liver lipi content
(Figure S2A,B). The activation of xenobiotic sensing nuclear receptor pregnane X receptor (PXR),
as the underlying cause for the increased liver weight, was excluded, since Pxr expression and the
expression of the PXR target gene Cyp3a11 remained unchanged (Figure S2C). The hepatic expression
of lipid synthesis and oxidation marker acyl-CoA synthetase long-chain family member 1 (Acsl1) was
unaffected, and lipid synthesis marker acetyl-CoA carboxylase 2 (Acc2) tended to be increased after
quercetin treatment (Figure 2C).
To assess the effect of quercetin on VLDL-TG production, we determined the mRNA expression
of hepatic micro omal triglyceride tra sfer protein (Mttp) and apolipoprotein B (Apob), which are
both involved in hepatic VLDL assembly and secretion (Figure 2C). Of note, quercetin d creased
Apob expression (−13%, p < 0.05; Figure 2C), which may indicate lower VLDL production.
To investigate whether quercetin reduced plasma TG levels due to an increased clearance of
TG-rich lipoproteins, we determined the kinetics of intravenous injected [3H]triolein (TO) labeled
TG-rich lipoprotein-like particles, and studied the plasma clearance of [3H]TO and organ uptake of
[3H]TO-derived [3H]oleate in mice treated with quercetin for 12 weeks. The plasma clearance of
[3H]TO was slightly accelerated in the quercetin-treated group (Figure 2D). An uptake of 3H per gram
organ was decreased in the liver (−22%, p < 0.05), but this effect disappeared when data were corrected
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for whole organ weight (Figure S2D). Interestingly, quercetin markedly increased (+60%, p < 0.05;
Figure 2E) the uptake of 3H per gram organ by subcutaneous WAT (sWAT), while the uptake by the
two studied classical BAT depots (interscapular and subscapular) were not changed. All in all, our data
suggest that quercetin decreases plasma TG levels by decreasing VLDL-TG production and increasing
TG-derived FA uptake by sWAT.
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p < 0.001 versus control. (g,s,v)WAT: gonadal, subcutaneous, visceral white adipose tissue; (i,s)BAT: 
interscapular, subscapular brown adipose tissue; qua: quadriceps muscle; sol: soleus muscle. 
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of this depot [17,18], we next determined whether quercetin had induced browning of sWAT. 
Indeed, quercetin markedly increased the expression of Ucp1 in sWAT (+229%, p < 0.05) as well as 
the brown fat marker fatty acid elongase 3 (Elovl3, +138%, p < 0.05, Figure 3A). The expression of 
other markers of BAT-like metabolism, including the transcriptional coregulators PR domain 
containing 16 (Prdm16) and cell death-inducing DFFA-like effector A (Cidea), the central inducer of 
mitochondrial biogenesis, peroxisome proliferator-activated receptor γ coactivator 1 (Pgc1α), and 
markers involved in lipid uptake, including lipoprotein lipase (Lpl), the LPL regulator 
angiopoietin-like 4 (Angptl4), and fatty acid translocase (Cd36) were unaltered in sWAT (Figure 3A). 
Also, the p-AMP-activated protein kinase (AMPK) (Thr172)/AMPK ratio in sWAT did not differ 
Figure 2. Quercetin reduces hepatic apolipoprotein B (Apob) expression and increases the uptake of
triglycerides (TG)-derived fatty acid (FA) by subcutaneous white adipose tissue. In week 2 and week
10 of the intervention, 24 h feces was collected (A) and used to determine fecal free fatty acid (FFA)
concentration (B). Gene expression in the liver was determined by qRT-PCR for acyl-CoA synthetase
long-chain family member 1 (Acsl1), acetyl-Co carboxylase 2 (Acc2), microsomal triglyceride transfer
protein (Mttp), and Apob (C). After 12 weeks, mice w re injected with glycerol tri[3H]oleate-labeled
lipoprotein-like particles, and clear nce from plasma (D) and uptake per gram organ (E) were
determined by 3H-activity analysis. Data are represented as mean ± SEM (n = 8–10); the expression of
genes was corrected for the reference gene β2-microglobulin, * p < 0.05, ** p < 0.01, *** p < 0.001 versus
control. (g,s,v)WAT: gonadal, subcutaneous, visceral white adipose tissue; (i,s)BAT: interscapular,
subscapular brown adipose tissue; qua: quadriceps muscle; sol: soleus muscle.
2.3. Quercetin Increases Ucp1 Gene Expression Specifically in sWAT
Sinc the in reased uptake of TG- erived FA by sWAT might point to the increased browning
of this depot [17,18], we next determin d whether quercetin had induced browning f sWAT.
Indeed, quercetin markedly increased the expression of Ucp1 in sWAT (+229%, p < 0.05) as well
as the brown fat marker fatty acid elongase 3 (Elovl3, +138%, p < 0.05, Figure 3A). The expression of
other markers of BAT-like metabolism, including the transcriptional coregulators PR domain containing
16 (Prdm16) and cell death-inducing DFFA-like effector A (Cidea), the central inducer of mitochondrial
biogenesis, peroxisome proliferator-activated receptor γ coactivator 1 (Pgc1α), and markers involved
in lipid uptake, including lipoprotein lipase (Lpl), the LPL regulator angiopoietin-like 4 (Angptl4),
and fatty acid translocase (Cd36) were unaltered in sWAT (Figure 3A). Also, the p-AMP-activated
protein kinase (AMPK) (Thr172)/AMPK ratio in sWAT did not differ between quercetin and the control
group (Figure S3A). Furthermore, quercetin did not increase the expression of Ucp1, Elovl3, Pgc1α,
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Lpl, Angptl4, and Cd36 in BAT (Figure 3B), gWAT (Figure S4A), and visceral WAT (vWAT, Figure S4B).
To verify browning on a morphological level, sWAT sections were stained with hematoxylin and
eosin (H&E) (Figure 3C), and examined for UCP-1 (Figure 3E). While relative cell size did not differ
between the two treatment groups (Figure 3D), quercetin did induce the presence of UCP-1 positive
cells (indicated by the arrows), while these were completely absent in the control animals (Figure 3E).
We also attempted to measure UCP-1 content in sWAT via western blot, but the content appeared
too low to draw conclusions (data not shown). Quercetin did not increase mitochondrial abundance,
since only the mitochondrial DNA versus nuclear DNA (mtDNA/nDNA) ratio of 16s/Hk2 tended
to be increased (p = 0.08, Figure S3B) in the quercetin-treated animals, while ratios of Cox2/Ucp2,
Cox2/Hk2, and 16S/Hk2 were unaffected. In line with the qRT-PCR data, quercetin did not affect
the histological appearance and lipid droplet content of BAT (Figure 3F,G), gWAT (Figure S4C,D),
and vWAT (Figure S4E,F). Also, quercetin did not affect the UCP-1 content in BAT (Figure 3H) or
UCP-1 protein content as measured via western blot (data not shown). All in all, our data shows that
quercetin increases the expression of BAT markers and UCP-1 content specifically in sWAT.
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Figure 3. Quercetin increases uncoupling protein-1 (Ucp1) gene expression specifically in 
subcutaneous white adipose tissue. Gene expression in sWAT (A) and BAT (B) was determined by 
qRT-PCR. Hematoxylin and eosin (H&E) staining was performed on paraffin-embedded sWAT 
sections, and representative pictures are shown (C). Pictures were analyzed in ImageJ to determine 
Figure 3. Quercetin increases uncoupling protein-1 (Ucp1) gene expression specifically in subcutaneous
white adipose tissu . Gene expression in sWAT (A) and BAT (B) was determined by qRT-PCR.
Hematoxylin and eosin (H&E) staining was performed on paraffin-embedded sWAT sections,
and representative pictures are shown (C). Pictures were analyzed in ImageJ to determine the relative
cell size (D). sWAT sections were stained for UCP-1 (arrows indicate UCP-1 positive cells, E) as
well. BAT sections were stained for H&E (F) and used to quantify lipid droplet content in ImageJ
(G). BAT sections were also stained for UCP-1 (H). Data are represented as mean ± SEM (n = 8–10);
the expression of genes was corrected for the reference gene β2-microglobulin (sWAT), Gapdh, and Hprt
(BAT), * p < 0.05 versus control. Bars (C,E,F,H) indicate 200 µm.
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3. Discussion
Previous studies in humans and animals have shown that quercetin is a possible new agent to
improve metabolic health, since it lowers plasma TG levels [7,13,14]. The organs involved in the
TG-lowering effect of quercetin remained obscure so far. In the current study, we demonstrated
that quercetin reduces plasma TG as well as FA levels, which is accompanied by an increased
flux of TG-derived FA towards sWAT, but not BAT, and the induction of browning of this depot.
Quercetin probably lowers VLDL-TG production, as indicated by lower Apob expression. We conclude
that the TG-lowering effect of quercetin may, at least in part, be due to increased TG-derived FA uptake
by sWAT as a consequence of browning (Figure 4).
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Figure 4. Proposed mechanism by whic quercetin lowers plasma triglycerides (TG). Plasma TG levels
are regulated by intestinal TG absorption, hepatic very-low density lipoprotein (VLDL)-TG production,
and the clearance of TG-derived fatty acids (FA) by peripheral organs such as sWAT in a process that
is dependent on lipoprotein lipase (LPL) (A). Quercetin induces the browning of sWAT, resulting in
an increased uptake of TG-derived FA by sWAT. This may contribute to the lowering of plasma TG
levels. Moreover, quercetin may also lower lipolysis from sWAT, which may contribute to lower
plasma free FA (FFA) levels and lower VLDL-TG production by the liver, also contributing to lower
plasma TG levels. Lastly, quercetin increases the uptake of lipids by the intestine, which apparently
does not counteract the re uction in plasma TG levels (B). Bold arrows indicat increased flux;
dashed arrows indicat decr ased flux. LDLr: low-density lipoprotein receptor; LRP: low-density
lipoprotein receptor-related protein.
Our finding that quercetin lowers plasma TG levels has been repeatedly shown by others [7,11,13,23].
Of note, in all of these studies, quercetin lowers plasma TG levels, even though different concentrations
(ranging from 0.025% to 0.33% w/w) of quercetin were added to a high-fat and/or high-fructose diet.
This indicates that quercetin is a potent modulator of plasma TG levels, and exerts metabolically beneficial
effects at a wide dose range. I contrast to our study, several of these studies also reported a reduction
in body weight following quercetin treatment, again in a dose range [7,11]. This discrepancy might
be explained by a difference in the age of the animals at the start of the intervention. Studies that
describe weight reduction after quercetin treatment used animals of 4–5 weeks of age, which are not
yet developed into adult mice, and might therefore be more susceptible to the body weight changes
caused by the intervention compared to the nine-week-old animals that were used in this study.
To gain insight into the mechanism underlying the TG-lowering effect of quercetin, we determined
the effect of quercetin on several metabolic organs and performed kinetic studies to assess FA fluxes.
To assess whether quercetin affected intestinal FA absorption, we measured fecal FA output. A previous
study in Caco-2 cells, which mimic human intestinal epithelial cells, shows that quercetin increases
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3H-FA uptake, but only when initial 3H-FA uptake was reduced under conditions of oxidative
stress [24]. However, fecal FA in our study was lower rather than higher in the quercetin-treated
group. This suggests higher rather than lower intestinal FA absorption, which therefore cannot
explain the observed reduction in plasma TG levels. Interestingly, we found that quercetin reduced
liver Apob expression, which might indicate lower VLDL production. In support of this hypothesis,
Gnoni et al. [25] found that the stimulation of isolated rat hepatocytes with quercetin decreases TG
synthesis and VLDL-TG formation due to lower ACC and diacylglycerol acyltransferase activity.
A lower VLDL-TG production might underlie the increase in liver weight in the quercetin-treated
animals by inducing a trend toward higher TG accumulation. Of note, this is in contrast to previous
literature, in which liver weight was shown to be unaffected [26] or even decreased, due to a reduction
in liver TG [11]. Next to a direct effect of quercetin on hepatocytes, a lower VLDL production in vivo
might also be the consequence of lower FA flux toward the liver due to reduced FA liberation by
lipolysis in WAT. In line with this, we showed that quercetin lowered plasma FFA levels, although we
did not find any effect of quercetin on the expression of markers of lipolysis in white adipose tissue
(not shown). Rather, others have shown that quercetin increases lipolysis in white adipocytes [15,27].
Alternatively, lower plasma FFA levels might also be a consequence of increased FFA uptake by
adipose depots, since not only TG-derived FA, but also FFA, can be taken up by BAT [28] and possibly
also by browned white adipose tissue.
Our kinetic study using labeled lipoprotein-like TG-rich particles showed that quercetin increases
the uptake of TG-derived FA specifically by sWAT, which is the depot that is especially prone to
browning [29]. This metabolic effect, along with increased Ucp1 and Elovl3 expression and the presence
of UCP-1 positive cells in sWAT, is fully compatible with increased browning. In agreement with
our results, Lee et al. [15] recently showed that onion peel, with quercetin as a main component,
induces Ucp1 expression in the white adipose tissue of mice. However, effects on plasma TG levels
were not reported in that study. Of note, we found that quercetin solely increased Ucp1 expression and
TG-derived FA uptake in sWAT, and did not affect uptake by BAT in our study. Adipose depot-specific
responses to intervention have been observed before. For instance, mice with genetically increased
levels of bone morphogenetic protein 4 are protected from obesity due to a phenotype with sWAT
browning, despite BAT accumulating lipids and adapting a beige/brite phenotype [30]. It can also be
questioned whether adipose tissue browning has the capacity to reduce plasma TG levels, since the
UCP-1 content in sWAT is quite low. Interestingly, inactivating the classical BAT depot by the selective
inhibition of lipid droplet lipolysis induces WAT browning and lowers TG levels in peripheral organs,
which indeed demonstrates the potency of browning per se to affect TG distribution [31], and possibly
also to reduce plasma TG levels. Our data thus suggest that quercetin induces browning that could,
at least in part, be responsible for the improved plasma TG levels (Figure 4). Future studies are
evidently needed to clarify the extent to which adipose tissue browning contributes to the metabolically
beneficial effects induced by quercetin.
How quercetin might induce the browning of sWAT has not yet been fully elucidated. Lee et al. [15]
proposed a mechanism by which quercetin acts directly on the adipocyte, and induces browning at
least in part via the AMP-activated protein kinase (AMPK)/sirtuin1/PGC1α pathway. Activation of
this pathway results in increased Pgc1α expression, suggesting an increase in mitochondrial biogenesis.
Although quercetin tended to slightly increase one of the four mtDNA/nDNA ratios in sWAT in our
study, quercetin did not affect the sWAT p-AMPK/AMPK ratio and Pgc1α expression. Interestingly,
quercetin is known as a phytoestrogen because of its binding capacity to the estrogen receptor
(ER) [32]. Pharmacological activation of the ER subtype β (ER-β) in mice reduces body weight and
adiposity with concomitant enhanced oxygen consumption and elevated core body temperature [33].
Moreover, ER-β ligand LY3201 induces browning of sWAT by modulating the sympathetic ganglia
and the adipocytes directly [34]. The mechanism underlying the quercetin-induced browning of
specifically sWAT, and the possible involvement of the ER-β remains to be determined, and would be
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an interesting avenue to pursue in future studies. In addition, whether quercetin induces browning in
humans, and whether this mediates the improvement of TG metabolism, remains to be studied.
In conclusion, our study shows that quercetin induces browning of sWAT, which results in
an increased flux of TG-derived FA towards sWAT and which may, at least in part, underlie the
TG-lowering effect of quercetin (Figure 4). The mechanism behind these effects and the ability of
quercetin to induce browning in humans remains to be determined.
4. Materials and Methods
4.1. Animals and Diet
Male C57Bl/6J mice (n = 18, Charles River Laboratories, Wilmington, MA, USA), nine weeks
of age, were placed on a run-in high-fat diet (HFD, 45% of calories derived from fat, D12451,
Research Diets, New Brunswick, NJ, USA) for three weeks. Next, mice were randomized based on
body weight and plasma TG levels to receive a HFD with or without quercetin (0.1% w/w) for 12 weeks.
Mice were housed individually under standard conditions with ad libitum access to food and water.
Mouse experiments were performed in accordance with the Institute for Laboratory Animal Research
Guide for the Care and Use of Laboratory Animals and have received approval from the University
Ethical Review Board (DEC14089, Leiden University Medical Center, Leiden, The Netherlands).
4.2. Body Weight, Body Composition and Food Intake
Body weight and body composition were determined weekly by using an EchoMRI-100 analyzer
(EchoMRI, Houston, TX, USA). Food intake was measured weekly by subtracting the amount of food
that was left in the cage from the amount given at the previous weighing.
4.3. Plasma Parameters
Before randomization and every three weeks thereafter, mice were fasted for four hours, and blood
was drawn from the tail vein. Blood was collected in paraoxon-coated capillaries (Sigma, St. Louis,
MO, USA) that were immediately placed on ice and centrifuged to obtain plasma. TG, total cholesterol
(TC), and glucose were determined using commercially available enzymatic kits (Roche Diagnostics,
Mannheim, Germany for TG and TC and Instruchemie, Delfzijl The Netherlands for glucose). FFA were
measured using an NEFA C kit (Wako Diagnostics, Instruchemie, Delfzijl, The Netherlands).
4.4. Lipoprotein Profiles
Plasma samples obtained after 12 weeks of intervention were pooled to determine cholesterol
distribution over plasma lipoproteins by fast performance liquid chromatography (FPLC). Plasma was
placed onto a Superose 6 column (ÄKTA System, Amersham Pharmacia Biotech, Piscataway, NJ, USA)
and eluted at a constant flow of 50 µL/min with phosphate buffered saline pH 7.4. Individual fractions
were measured for TC, as described above.
4.5. Indirect Calorimetry and Physical Activity
During the third week of treatment, mice (n = 8 per group) were placed in fully automatic
metabolic cages (LabMaster System, TSE Systems, Bad Homburg, Germany) to assess energy
expenditure and physical activity levels. After 20 h of acclimatization, oxygen uptake (V· O2) and
carbon dioxide production (V· CO2) were measured for five consecutive days. Total energy expenditure
(EE) was calculated from V· O2 and V· CO2 using the Weir equation [35]. Fat and glucose oxidation
rates were calculated from V· O2 and V· CO2, as described previously [36]. Physical activity was
measured using infrared sensor frames.
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4.6. Feces Collection and Fecal FFA Concentration
After two and 10 weeks of intervention, feces was collected by placing the mice in cages with
new bedding and removing feces 24 h later. Feces was then dried and weighed, approximately
30 mg was ground, and fecal FFA were determined after methyl esterification using the NEFA C kit
(Wako Diagnostics), as described previously [37].
4.7. RNA Isolation and qRT-PCR Analysis
Total RNA was isolated using TriPure Isolation reagent (Roche obtained via Sigma, St. Louis, MO,
USA ) following the manufacturer’s protocol. cDNA was made using Moloney Murine Leukemia Virus
Reverse Transcriptase (Promega, Leiden, The Netherlands). Quantitative real-time PCR (qRT-PCR) was
performed with SYBR green (Promega) on a CFX96 PCR Machine (Bio-Rad, Veenendaal, The Netherlands).
mRNA expression levels were normalized to β2-microglobulin or glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) and hypoxanthine guanine phosphoribosyl transferase (Hprt) as reference
genes. Primer sequences are listed in Table 1.
Table 1. List of qRT-PCR primer sequences.


















4.8. In Vivo Clearance of Radiolabeled Lipoprotein-Like Particles
Lipoprotein-like particles (80 nm) labeled with glycerol tri[3H]oleate (triolein, [3H]TO) were
prepared and characterized as described previously [38]. Mice were fasted for 4 h and injected (t = 0)
with 200 µL of [3H]TO-labeled lipoprotein-like particles (1.0 mg TG per mouse) via the tail vein.
Blood samples were taken 2, 5, 10, and 15 min after injection to determine the plasma decay of [3H]TO
(using calculations described in [39]). Next, mice were sacrificed by means of cervical dislocation
and perfused with ice-cold heparin solution (0.1% v/v in PBS) via the heart. Organs were harvested,
weighed, and the uptake of [3H]TO-derived radioactivity was quantified and expressed per gram or
whole organ wet tissue weight.
4.9. Histology
Interscapular BAT, gonadal WAT (gWAT), subcutaneous WAT (sWAT), visceral WAT (vWAT),
and liver were removed and directly placed in 4% paraformaldehyde, dehydrated, and embedded
in paraffin. Hematoxylin and Eosin staining were performed using standard protocols. An overview
of the studied fat depots can be found in Figure S5. Relative cell size and intracellular lipid content
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was quantified using ImageJ (version 1.49). UCP-1 staining on sWAT and BAT were performed as
described before [39].
4.10. Quantification of Lipid Content in Liver
Liver samples (approx. 50 mg) were homogenized in 10 µL of ice-cold methanol per mg of tissue.
Lipids were extracted as described before [39]. Hepatic TG, TC, and PL concentrations were measured
using commercial kits (as explained in Plasma parameters). Liver lipids were expressed per milligram of
protein, which was determined using a Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA).
4.11. Protein Isolation and Western Blot
sWAT samples were lysed in buffer containing 50 mM of
N-(2-Hydroxyethyl)piperazine-N’-2-ethanesulfonic Acid (HEPES, pH 7.6), 50 mM of NaF, 50 mM
of KCl, 5 mM of NaPPi, 1 mM of ethylenediaminetetraacetic acid (EDTA), 1 mM of ethylene
glycol tetraacetic acid (EGTA), 1 mM of dithiothreitol (DTT), 5 mM of β-glycerophosphate, 1 mM
of sodium vanadate, 1% of Nonidet P-40, and protease inhibitors using cocktail tablets (Roche).
Protein concentration was determined using the Pierce BCA Protein Assay kit (Thermo Scientific),
and extracts were diluted in Laemli buffer. Next, 10 µg of sWAT protein was separated on
a 10% polyacrylamide gel (#456-8035, Bio-Rad) by electrophoresis and turbo-blotted on nitrocellulose
membranes (#170-4159, Trans-blot Turbo, Bio-Rad). Membranes were blocked for 1 h at room
temperature in Tween-20 buffer with 5% non-fat dry milk. Next, membranes were incubated overnight
with 1:1000 or 1:5000 (only for UCP-1 in BAT) diluted specific primary antibodies. Primary antibodies
specific for AMPKα (#2532), p-AMPKα (Thr172, #2535), and α/β-Tubulin (#2148) were purchased
from Cell Signalling Technology (Leiden, The Netherlands) and the antibody specific for UCP-1
(#U6382) was purchased from Sigma (St. Louis, MO, USA). A primary antibody specific for Gapdh
was purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Membranes were incubated
with horseradish peroxidase-conjugated secondary antibodies for 1 h. Super Signal West Pico
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA) was used to visualize bands
on the ChemiDocTM Touch imaging system (Bio-Rad). The images were analyzed with Image lab
software (version 5.2, Bio-Rad), and protein content was corrected for GAPDH (housekeeping protein).
4.12. Determination of mtDNA/nDNA Ratio
Total DNA was isolated from sWAT with QIAamp DNA Mini Kit (no. 51306; Qiagen, Hilden,
Germany), following the provided manufacturer’s protocol. The PCR reaction was performed in
a LightCycler 480 (Roche). The reaction mix contained 500 pg of DNA, 1.25 µM of forward and reverse
primer, and 4 µL of 2× SYBR green master mix (Roche) in a final volume of 8 µL. Then, 16S and
Cox2 were used as mitochondrial-encoded genes, and Hk2 and Ucp2 were used as nuclear-encoded
genes. Primer sequences are listed in Table 2. Data were analyzed with LightCycler software
release 1.5.0 (Roche). The mean PCR efficiency was calculated to assess gene expression levels using
LinRegPCR program version 12.17 [40].
Table 2. List of PCR primer sequences.
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4.13. Statistical Analysis
All of the data are expressed as mean ± SEM. Statistical analysis was performed with an IBM
SPSS Statistics 23 software package (SPSS, Chicago, IL, USA). The differences between control and
quercetin were determined using an unpaired two-tailed t-test. Plasma decay in the clearance was
analyzed using repeated ANOVA measurements with Sidak’s post hoc test. A p-value < 0.05 was
considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/6/1786/
s1.
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Abbreviations
ACC2; Acc2 acetyl-CoA carboxylase 2
ACSL1; Acsl1 long-chain-fatty-acid-CoA ligase 1
AMPK AMP-activated protein kinase
APOB; Apob apolipoprotein B
ANGPTL4; Angptl4 angiopoietin-like 4
(i)BAT (interscapular) brown adipose tissue
CD36; Cd36 fatty acid translocase
EE energy expenditure
ELOVL3; Elovl3 fatty acid elongase 3
(F)FA (free) fatty acids
HFD high fat diet
LDLr low density lipoprotein receptor
LPL; Lpl lipoprotein lipase
LRP low density lipoprotein receptor-related protein
MTP; Mttp microsomal triglyceride transfer protein
PGC1α; Pgc1α peroxisome proliferator-activated receptor γ coactivator 1α
PXR; Pxr pregnane X receptor





UCP-1; Ucp1 uncoupling protein-1
VLDL very-low density lipoprotein
(g,s,v)WAT (gonadal, subcutaneous, visceral) white adipose tissue
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